Advanced Emissions Solutions provides emissions reductions technologies through consumables that utilize powdered activated carbon (PAC) and chemical based technologies, primarily serving the coal-fired power generation and industrial boiler industries. The company's operations consisted of two reportable segments: refined coal, which engages in equity method investments as well as royalty related to reduced emissions of both nitrogen oxide and mercury from coal; and Power Generation and Industrials, which sells consumable products that utilize PAC and chemical technologies as well as historically the sale of activated carbon injection and dry sorbent injection equipment systems.

Anixa Biosciences is a biotechnology company focused on using the body's immune system to diagnose, treat and prevent cancer. The company's subsidiary, Anixa Diagnostics Corporation, develops Cchek?, a platform for non-invasive blood tests for the early detection of cancer. The company's subsidiary, Certainty Therapeutics, Inc., develops immuno-therapy drugs against cancer. The company has focused on the development of a treatment for ovarian cancer. The company is also engaged in limited patent licensing activities in the area of encrypted audio/video conference calling.

Apple designs, manufactures and markets smartphones, personal computers, tablets, wearables and accessories, and sells a variety of related services. The company's products include: iPhone; Mac; iPad; and wearables, home and accessories, which includes AirPods?, Apple TV?, Apple Watch?, Beats? products, HomePod?, iPod touch? and other Apple-branded and third-party accessories. The company's services include: digital content stores and streaming services; AppleCare, which includes AppleCare + (AC+) and the AppleCare Protection Plan; iCloud, which is the company's cloud service; licensing; and other services, which include Apple Arcade?, Apple Card?, Apple News+, and Apple Pay, a cashless payment service.

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. The company's main product candidate, AT-007, is a central nervous system, penetrant AR inhibitor (ARI) that the company is developing for the treatment of galactosemia, a rare pediatric metabolic disease that affects how the body processes a simple sugar called galactose. The company's second product candidate, AT-001, is an ARI with systemic exposure and peripheral nerve permeability that the company is developing for the treatment of diabetic cardiomyopathy, a fatal fibrosis of the heart.

Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The company's product candidates comprised of: NYX 2925, which is a small molecule N-methyl-D-aspartate receptors (NMDAr) modulator being developed for the treatment of chronic pain; NYX-783, which is a small-molecule NMDAr modulator in development for the treatment of post-traumatic stress disorder; NYX-458, which is a small-molecule NMDAr modulator in development for the treatment of Parkinson's disease cognitive impairment; and AGN-241751, which is for the treatment of depressive disorder.

Arvinas is a biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. The company is developing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. The company has initiated a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer. The company is developing ARV-471, a PROTAC targeted protein degrader targeting the estrogen receptor protein, or ER, for the treatment of women with locally advanced or metastatic ER positive / HER2 negative breast cancer.

AXT is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The company's compound substrates combine indium with phosphorous (indium phosphide: InP) or gallium with arsenic (gallium arsenide: GaAs). InP is a semiconductor substrate used in, among others, fiber optic lasers and detectors, passive optical networks, metro and data center connectivity, silicon photonics, infrared motion control and infrared thermal imaging. The company also makes semi-insulating GaAs substrates used in making semiconductor chips in applications such as power amplifiers for wireless devices, transistors and solar cells for drones. In addition, the company sells certain raw materials.

Ballantyne Strong is a holding company. Through its subsidiaries, the company is focused on serving the cinema, retail, financial, advertising and government markets. The company conducts its operations through three operating segments: Strong Cinema, which provides projection screens, technical support services and other related products to the cinema exhibition industry; Convergent, which delivers digital signage solutions and services to various enterprise markets, including retail, banking and healthcare, as well as certain government agencies and Digital-Out-Of-Home advertising network operators; and Strong Outdoor, which provides advertising services and experiential marketing services.

BroadVision develops, markets, and supports enterprise portal applications that enable companies to unify their e-business infrastructure and conduct interactions and transactions with employees, partners, and customers through a personalized self-service model. The company's offerings consist of a framework for personalization and self-service, modular applications and toolsets that customers use to create e-commerce, portal solutions, and enterprise social networking, and collaboration and knowledge management solutions. The company's primary product offerings are software solutions. The company's solutions include Business Agility Suite, Commerce Agility Suite, Clearvale, Clear, QuickSilver and Vmoso.

Cadence is a bank holding company. The company is engaged in commercial lending to middle-market customers and provide a range of commercial loans to middle-market commercial businesses, individuals and business owners. The company's loan portfolio includes commercial and industrial loans, residential real estate loans, commercial real estate loans and other consumer loans. The company also provides its customers a variety of deposit products, including checking accounts, savings accounts, money market accounts and other deposit accounts, through multiple channels, including its network of full-service branches, drive-thru branches, ATMs, ITMs, and its online, mobile and telephone banking platforms.

cbdMD is a branding and marketing company. Through its CBD Industries LLC subsidiary, the company produces and distributes various cannabidiol (CBD) products, including tinctures, capsules, gummies, bath bombs and topical creams. The company has a line of pet related CBD products under its Paw CBD brand which includes tinctures, treats, and balms. The company's website provides information about CBD quality and existing industry events, as well as United States based customer service. The company tests its hybrid CBD extractions through independent, third-party laboratories. The company's products are available online at www.cbdMD.com and non-affiliated stores.

Cidara Therapeutics is a biotechnology company focused on the discovery, development and commercialization of anti-infectives for the treatment and prevention of diseases. The company is developing a pipeline of product and development candidates, with a focus on fungal and infections. The company's primary product candidate is rezafungin acetate, an intravenous formulation of a echinocandin. Rezafungin is being developed as a once-weekly therapy for the first-line treatment and prevention of fungal infections. In addition, the company is using its Cloudbreak? platform to develop Antiviral Fc-Conjugates, for the prevention and treatment of influenza and other infections.

Enterprise Products Partners is a provider of midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals and refined products. The company's midstream energy operations include: natural gas gathering, treating, processing, transportation and storage; NGL transportation, fractionation, storage, and export and import terminals; crude oil gathering, transportation, storage, and export and import terminals; petrochemical and refined products transportation, storage, export and import terminals, and related services; and a marine transportation business that operates primarily on the U.S. inland and Intracoastal Waterway systems.

Frequency Electronics is engaged in precision time and frequency generation technology. The company's segments are: FEI-NY and FEI-Zyfer. The FEI-NY segment includes the operations of the company's wholly-owned subsidiaries, FEI-Asia and FEI-Elcom. FEI-Asia functions as a manufacturing facility for FEI-NY and FEI-Zyfer. FEI-Elcom provides design and technical support for the FEI-NY segment's business. The FEI-Zyfer segment designs and manufactures products which incorporate global positioning systems technologies and clocks designed and manufactured at FEI-NY. FEI-Zyfer sells its products to both commercial and U.S. Government customers and collaborates with FEI-NY on joint product development activities.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. The company is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and other hematologic cancers. The company is also developing an additional drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4.

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

Good Times Restaurants operates and franchises Bad Daddy's Burger Bar restaurants (Bad Daddy's) and Good Times Burgers & Frozen Custard (Good Times) restaurants. Bad Daddy's and Good Times are two distinctly different, yet complementary, restaurant concepts. Bad Daddy's operates in the casual dining segment of the restaurant industry. Bad Daddy's operates all of its company-owned restaurants under a table service / full-bar service model. The menu is comprised of burgers, salads, sandwiches, and appetizers. Good Times is a quick service restaurant concept offering hand crafted products. Good Times provides a menu of Angus beef and chicken.

Heritage Commerce is a bank holding company. Through its subsidiary, Heritage Bank of Commerce, the company provides a range of commercial banking services to small and medium-sized businesses and their owners, managers and employees. The company's lending activities include commercial, real estate, construction and land development, consumer and Small Business Administration guaranteed loans. The company provides a range of deposit products for business banking and retail markets. The company provides a multitude of other products and services to complement its lending and deposit services. In addition, the company's subsidiary, Bay View Funding, provides factoring financing throughout the United States.

La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for patients suffering from life-threatening diseases. GIAPREZATM (angiotensin II) is approved by the United States Food and Drug Administration as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. LJPC-0118 is the company's investigational product for the treatment of severe malaria. LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product, is being developed for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia and polycythemia vera.

Lovesac is a technology omni-channel company that designs, manufactures and sells furniture comprised of couches called Sactionals and foam beanbag chairs called Sacs. The company markets and sells its products through showrooms and online sales.

Marchex is a call analytics company that helps businesses connect, drive, measure and convert callers into customers. The company's primary product offerings include: Marchex Call Analytics, which is an analytics platform for enterprises; Marchex Display and Video Analytics, which is a product for marketers that buy digital display advertising; Marchex Site Analytics, which is a product for marketers that can drive phone calls from websites; Marchex Social Analytics, which is a product for marketers that buy social media advertising; Marchex Call Marketplace, which is a mobile advertising network for businesses; and Local Leads, which is an advertising solution for small business resellers.

On Track Innovations and its subsidiaries are principally engaged in the field of design and development of cashless payment solutions. Co. operates in two segments: Retail and Mass Transit Ticketing; which includes selling and marketing variety of products for cashless payment solutions for the retail market and mass transit ticketing; and Petroleum, which includes manufacturing and selling of fuel payment and management solutions. In addition, certain products for the medical industry and other secure smart card solutions are classified under Other segment. Co. focuses on providing cashless payment solutions based among other things on its contactless near field communications technology.

PBF Energy is a holding company. Through its subsidiaries, the company is engaged as an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants and other petroleum products in the U.S. The company operates in two business segments: refining, which the company produces a variety of products at each of its refineries such as gasoline, ultra-low-sulfur diesel, heating oil, jet fuel, lubricants, petrochemicals and asphalt; and logistics, which through its PBF Logistics LP subsidiary, the company owns or leases, operates, develops and acquires crude oil and refined petroleum products terminals, pipelines, storage facilities and similar logistics assets.

PNC Financial Services Group is a bank holding company. The company has businesses engaged in retail banking, including residential mortgage, corporate and institutional banking and asset management, providing its products and services nationally. The company's segments are: Retail Banking, which provides deposit, lending, brokerage, insurance services, investment management and cash management products and services; Corporate and Institutional Banking, which provides lending, treasury management, and capital markets-related products and services; Asset Management Group, which provides personal wealth management; and BlackRock, which provides a range of investment and technology services.

Safehold is a holding company. Through its subsidiaries, the company operates its business through one segment by acquiring, managing and capitalizing ground leases. Ground leases generally represent the ownership of land underlying commercial real estate properties, which are leased on a long-term basis (base terms are 30 to 99 years, often with tenant renewal options) by the land owner to a tenant that owns and operates the building on top of the land, or what the company refer to as a Safehold?.

Standard AVB Financial is a bank holding company. Through its subsidiary, Standard Bank, PaSB (the Bank), the company provides financial services to individuals, families and businesses. The Bank's business consists primarily of accepting deposits from the general public and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial business loans, one- to four-family residential mortgage loans, home equity loans and lines of credit and investment securities. The Bank also originates construction loans and consumer loans. The Bank's deposit accounts consist of savings accounts, certificates of deposit and checking accounts.

Taylor Devices is engaged in the design, development, manufacture and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment and structures. These products include: Seismic Dampers, which mitigate the effects of earthquake tremors on structures; Fluidicshoks?, which are shock absorbers for use in the defense, aerospace and commercial industry; Crane and Industrial Buffers, which used for industrial application on cranes, ships, container ships, railroad cars, truck docks, ladle and ingot cars, ore trolleys and car stops; and Self-Adjusting Shock Absorbers, which are designed for high cycle application in heavy industry.

Vaccinex is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. The company is engaged in the field of semaphorin 4D (SEMA4D) biology, targeting SEMA4D as a potential treatment for cancer, neurodegenerative diseases, or autoimmune disorders. The company is utilizing its SEMA4D antibody platform to develop its primary product candidate, pepinemab (VX15/2503), an antibody that utilizes mechanisms of action. The company is focused on the development of pepinemab for the treatment of non-small cell lung cancer, Huntington's disease, and Alzheimer's disease.

vTv Therapeutics is a holding company. Through its subsidiaries, the company is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates. The company's drug candidate for the treatment of Alzheimer's disease, azeliragon (TTP488), is an orally administered small molecule antagonist targeting the receptor for advanced glycation endproducts. The company's type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor. The company is also developing TTP399 for type 1 diabetes.